Clinical Trials Directory

Trials / Conditions / Clostridium Infections

Clostridium Infections

15 registered clinical trials studyying Clostridium Infections.

StatusTrialSponsorPhase
CompletedC.Difficile Observational Study
NCT06277999
AstraZeneca—
WithdrawnBezlotoxumab Versus FMT for Multiple Recurrent CDI
NCT05077085
Leiden University Medical CenterPhase 4
CompletedSafety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy A
NCT04026009
GlaxoSmithKlinePhase 1
UnknownStudy on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
NCT04179201
Xijing Hospital—
CompletedA Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
NCT02563106
Theriva Biologics, Inc.Phase 2
UnknownMicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation
NCT02681068
University of Cologne—
CompletedClinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genot
NCT00446355
University of Pittsburgh—
TerminatedStudy of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
NCT00384527
Romark Laboratories L.C.Phase 3
CompletedPAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
NCT00468728
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 3
CompletedStudy of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Pati
NCT00350298
MassBiologicsPhase 2
CompletedFidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-0
NCT00314951
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 3
CompletedEfficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Pa
NCT00328263
Bio-K Plus International Inc.Phase 3
CompletedA Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
NCT00269399
Bausch Health Americas, Inc.Phase 3
CompletedSafety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Voluntee
NCT00214461
SanofiPhase 1
CompletedSafety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volu
NCT00127803
SanofiPhase 1